US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(fr)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotique C-15003 PHO et sa préparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
WO1982001188A1
(fr)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
Composes 4,5-deoxymaytansinoide et leur procede de preparation
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
JPS6098584A
(ja)
|
1983-11-02 |
1985-06-01 |
Canon Inc |
カメラ―体形vtr
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
FI102355B1
(fi)
|
1988-02-11 |
1998-11-30 |
Bristol Myers Squibb Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
|
AU634186B2
(en)
|
1988-11-11 |
1993-02-18 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
CA2023779A1
(fr)
|
1989-08-23 |
1991-02-24 |
Margaret D. Moore |
Composes et methodes pour la detection et le traitement des infections a virus epstein-barr et des troubles de l'immunite
|
CA2026147C
(fr)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5256643A
(en)
|
1990-05-29 |
1993-10-26 |
The Government Of The United States |
Human cripto protein
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
WO1992007574A1
(fr)
|
1990-10-25 |
1992-05-14 |
Tanox Biosystems, Inc. |
Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
DK0577752T4
(da)
|
1991-03-29 |
2007-10-22 |
Genentech Inc |
Human PF4A receptorer og deres anvendelse
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
EP0590058B1
(fr)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
ANTICORP HUMANISE specifique pour heregulin
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
JP3050424B2
(ja)
|
1991-07-12 |
2000-06-12 |
塩野義製薬株式会社 |
ヒトエンドセリンリセプター
|
US5264557A
(en)
|
1991-08-23 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Polypeptide of a human cripto-related gene, CR-3
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(fr)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions induisant la destruction de cellules infectees par l'hiv
|
US6153408A
(en)
|
1991-11-15 |
2000-11-28 |
Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
US6011146A
(en)
|
1991-11-15 |
2000-01-04 |
Institut Pasteur |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
EP0563475B1
(fr)
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Conjugués d'agents ciblés et de dérivés du CC-1065
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
IL107366A
(en)
|
1992-10-23 |
2003-03-12 |
Chugai Pharmaceutical Co Ltd |
Genes coding for megakaryocyte potentiator
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5644033A
(en)
|
1992-12-22 |
1997-07-01 |
Health Research, Inc. |
Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
EP0714409A1
(fr)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Anticorps
|
US5773223A
(en)
|
1993-09-02 |
1998-06-30 |
Chiron Corporation |
Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
|
KR100332254B1
(ko)
|
1993-10-01 |
2002-09-27 |
데이꼬꾸 조끼 세이야꾸 가부시키가이샤 |
신규인펩티드유도체
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5750370A
(en)
|
1995-06-06 |
1998-05-12 |
Human Genome Sciences, Inc. |
Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5707829A
(en)
|
1995-08-11 |
1998-01-13 |
Genetics Institute, Inc. |
DNA sequences and secreted proteins encoded thereby
|
US20020193567A1
(en)
|
1995-08-11 |
2002-12-19 |
Genetics Institute, Inc. |
Secreted proteins and polynucleotides encoding them
|
JP3646191B2
(ja)
|
1996-03-19 |
2005-05-11 |
大塚製薬株式会社 |
ヒト遺伝子
|
NZ332598A
(en)
|
1996-05-17 |
2000-04-28 |
Schering Corp |
Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell
|
GB2315067B
(en)
|
1996-07-11 |
2000-02-16 |
Pharmacia Spa |
Morpholinyl anthracycline derivatives
|
US5945511A
(en)
|
1997-02-20 |
1999-08-31 |
Zymogenetics, Inc. |
Class II cytokine receptor
|
US7033827B2
(en)
|
1997-02-25 |
2006-04-25 |
Corixa Corporation |
Prostate-specific polynucleotide compositions
|
US20030185830A1
(en)
|
1997-02-25 |
2003-10-02 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US6541212B2
(en)
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
US6261791B1
(en)
|
1997-03-10 |
2001-07-17 |
The Regents Of The University Of California |
Method for diagnosing cancer using specific PSCA antibodies
|
CA2281877C
(fr)
|
1997-03-10 |
2010-01-05 |
The Regents Of The University Of California |
Antigene de cellule souche prostatique (psca)
|
US6555339B1
(en)
|
1997-04-14 |
2003-04-29 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated human protein-coupled receptors
|
US6319688B1
(en)
|
1997-04-28 |
2001-11-20 |
Smithkline Beecham Corporation |
Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
|
AU751659B2
(en)
|
1997-05-02 |
2002-08-22 |
Genentech Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
WO1998051824A1
(fr)
|
1997-05-15 |
1998-11-19 |
Abbott Laboratories |
Reactifs et procedes utiles au depistage de maladies du tractus urinaire
|
US6890749B2
(en)
|
1997-05-15 |
2005-05-10 |
Abbott Laboratories |
Reagents and methods useful for detecting diseases of the prostate
|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
US20030060612A1
(en)
|
1997-10-28 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20020034749A1
(en)
|
1997-11-18 |
2002-03-21 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
US6110695A
(en)
|
1997-12-02 |
2000-08-29 |
The Regents Of The University Of California |
Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
|
PT1034298E
(pt)
|
1997-12-05 |
2012-02-03 |
Scripps Research Inst |
Humanização de anticorpo murino
|
WO2004031238A2
(fr)
|
2002-10-03 |
2004-04-15 |
Mcgill Univeristy |
Agents de liaison d'antigenes carcinoembryonnaires (cea) permettant d'inverser les effets tumorigenes a mediation cea sur des cellules cancereuses humaines et leurs utilisations
|
JP4603157B2
(ja)
|
1998-03-13 |
2010-12-22 |
ザ バーナム インスティチュート |
種々の選択された器官または組織にホーミングする分子
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
CA2331846C
(fr)
|
1998-05-13 |
2010-01-12 |
Epimmune Inc. |
Vecteurs d'expression destines a stimuler une reponse immunitaire et procedes de leur utilisation
|
US20020187472A1
(en)
|
2001-03-09 |
2002-12-12 |
Preeti Lal |
Steap-related protein
|
US20030064397A1
(en)
|
1998-05-22 |
2003-04-03 |
Incyte Genomics, Inc. |
Transmembrane protein differentially expressed in prostate and lung tumors
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
WO2000012130A1
(fr)
|
1998-08-27 |
2000-03-09 |
Smithkline Beecham Corporation |
Agonistes et antagonistes de rp105
|
ATE240334T1
(de)
|
1998-08-27 |
2003-05-15 |
Spirogen Ltd |
Pyrrolobenzodiazepine
|
JP4689781B2
(ja)
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
AU5963699A
(en)
|
1998-10-02 |
2000-04-26 |
Mcmaster University |
Spliced form of (erb)b-2/neu oncogene
|
US6946261B1
(en)
|
1998-11-20 |
2005-09-20 |
Migenix Inc. |
Efficient methods for producing anti-microbial cationic peptides in host cells
|
WO2001057188A2
(fr)
|
2000-02-03 |
2001-08-09 |
Hyseq, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US20030091580A1
(en)
|
2001-06-18 |
2003-05-15 |
Mitcham Jennifer L. |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6962980B2
(en)
|
1999-09-24 |
2005-11-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6858710B2
(en)
|
1998-12-17 |
2005-02-22 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6468546B1
(en)
|
1998-12-17 |
2002-10-22 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of ovarian cancer
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
DE69939553D1
(de)
|
1998-12-30 |
2008-10-23 |
Beth Israel Hospital |
Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP2386574A3
(fr)
|
1999-01-15 |
2012-06-27 |
Genentech, Inc. |
Variantes de polypeptide et fonction effectrice altérée
|
CZ20012587A3
(cs)
|
1999-01-29 |
2002-05-15 |
Corixa Corporation |
Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu
|
GB9905124D0
(en)
|
1999-03-05 |
1999-04-28 |
Smithkline Beecham Biolog |
Novel compounds
|
US7232889B2
(en)
|
1999-03-08 |
2007-06-19 |
Genentech, Inc. |
PRO300 antibodies
|
AU3395900A
(en)
|
1999-03-12 |
2000-10-04 |
Human Genome Sciences, Inc. |
Human lung cancer associated gene sequences and polypeptides
|
US7312303B2
(en)
|
1999-05-11 |
2007-12-25 |
Genentech, Inc. |
Anti-PRO4980 antibodies
|
CA2370466C
(fr)
|
1999-06-25 |
2011-02-08 |
Sharon Erickson |
Techniques de traitement utilisant des conjugues maytansinoides-anticorps anti-erbb
|
WO2000075655A1
(fr)
|
1999-06-03 |
2000-12-14 |
Takeda Chemical Industries, Ltd. |
Procede de criblage avec cd100
|
US20030119113A1
(en)
|
1999-07-20 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7297770B2
(en)
|
1999-08-10 |
2007-11-20 |
Genentech, Inc. |
PRO6496 polypeptides
|
US7294696B2
(en)
|
1999-08-17 |
2007-11-13 |
Genentech Inc. |
PRO7168 polypeptides
|
CA2380355A1
(fr)
|
1999-09-01 |
2001-03-08 |
Genentech, Inc. |
Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
|
US20030232056A1
(en)
|
1999-09-10 |
2003-12-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030206918A1
(en)
|
1999-09-10 |
2003-11-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030129192A1
(en)
|
1999-09-10 |
2003-07-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
ES2309012T3
(es)
|
1999-10-29 |
2008-12-16 |
Genentech, Inc. |
Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
|
EP2316843B1
(fr)
|
1999-11-29 |
2015-10-14 |
The Trustees of Columbia University in the City of New York |
Isolation de cinq nouveaux gènes codant pour le mélanome de type récepteur Fc impliqué dans la pathogenèse du lymphome-mélanome
|
CA2392510A1
(fr)
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
|
CA2393738A1
(fr)
|
1999-12-10 |
2001-06-14 |
Epimmune Inc. |
Induction de reponses immunes cellulaires a her2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques
|
AU784983B2
(en)
|
1999-12-15 |
2006-08-17 |
Genentech Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
ATE459369T1
(de)
|
1999-12-23 |
2010-03-15 |
Zymogenetics Inc |
Verfahren zur behandlung von entzündungen
|
ATE485306T1
(de)
|
1999-12-23 |
2010-11-15 |
Zymogenetics Inc |
Löslicher interleukin-20-rezeptor
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
NZ502058A
(en)
|
1999-12-23 |
2003-11-28 |
Ovita Ltd |
Isolated mutated nucleic acid molecule for regulation of ovulation rate
|
CA2395660A1
(fr)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Agents cytotoxiques comprenant des doxorubicines et des daunorubicines modifiees et utilisation therapeutique de ceux-ci
|
US7294695B2
(en)
|
2000-01-20 |
2007-11-13 |
Genentech, Inc. |
PRO10268 polypeptides
|
US20030224379A1
(en)
|
2000-01-21 |
2003-12-04 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
WO2001053463A2
(fr)
|
2000-01-21 |
2001-07-26 |
Corixa Corporation |
COMPOSES ET PROCEDES DE PREVENTION ET DE TRAITEMENT DE MALIGNITES ASSOCIEES A HER-2/neu
|
US20030104562A1
(en)
|
2000-02-11 |
2003-06-05 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
AU2001238596A1
(en)
|
2000-02-22 |
2001-09-03 |
Millennium Pharmaceuticals, Inc. |
18607, a novel human calcium channel
|
US20030219806A1
(en)
|
2000-02-22 |
2003-11-27 |
Millennium Pharmaceuticals, Inc. |
Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
|
US20040005561A1
(en)
|
2000-03-01 |
2004-01-08 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AU2001245280A1
(en)
|
2000-03-07 |
2001-09-17 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
WO2002088170A2
(fr)
|
2001-04-26 |
2002-11-07 |
Biogen, Inc. |
Anticorps de blocage cripto et utilisations correspondantes
|
AU4941101A
(en)
|
2000-03-24 |
2001-10-08 |
Fahri Saatcioglu |
Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
|
AU2001250412A1
(en)
|
2000-03-31 |
2001-10-08 |
Ipf Pharmaceuticals Gmbh |
Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
|
AU2001253140A1
(en)
|
2000-04-03 |
2001-10-15 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Tumor markers in ovarian cancer
|
CA2402392A1
(fr)
|
2000-04-07 |
2001-10-18 |
Arena Pharmaceuticals, Inc. |
Recepteurs connus couples a la proteine g non endogenes a activation constitutive
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
WO2001088133A2
(fr)
|
2000-05-18 |
2001-11-22 |
Lexicon Genetics Incorporated |
Nouveaux homologues humains de semaphorine et polynucleotides codant ceux-ci
|
AU2001274888A1
(en)
|
2000-05-19 |
2001-12-03 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
WO2001094641A2
(fr)
|
2000-06-09 |
2001-12-13 |
Idec Pharmaceuticals Corporation |
Nouvelles cibles geniques et ligands se fixant a celles-ci pour le traitement et le diagnostic de carcinomes ovariens
|
AU2001268471A1
(en)
|
2000-06-16 |
2002-01-02 |
Incyte Genomics, Inc. |
G-protein coupled receptors
|
AU2001273194A1
(en)
|
2000-06-30 |
2002-01-14 |
Amgen Inc. |
B7-Like Molecules and Uses Thereof
|
CA2406649A1
(fr)
|
2000-06-30 |
2002-01-10 |
Human Genome Sciences, Inc. |
Polynucleotides du type b7, polypeptides et anticorps en rapport
|
CA2413186A1
(fr)
|
2000-06-30 |
2002-01-10 |
Incyte Genomics, Inc. |
Molecules de matrice extracellulaire et d'adhesion cellulaire
|
AU2002214531A1
(en)
|
2000-07-03 |
2002-01-30 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040044179A1
(en)
|
2000-07-25 |
2004-03-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6891030B2
(en)
|
2000-07-27 |
2005-05-10 |
Mayo Foundation For Medical Education And Research |
T-cell immunoregulatory molecule
|
WO2002010382A2
(fr)
|
2000-07-28 |
2002-02-07 |
Ulrich Wissenbach |
Marqueurs trp8, trp9 et trp10 associes au cancer
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
IL154415A0
(en)
|
2000-08-14 |
2003-09-17 |
Corixa Corp |
Polynucleotides that encode her-2/neu polypeptides and pharmaceutical compositions containing the same
|
WO2002013847A2
(fr)
|
2000-08-14 |
2002-02-21 |
Corixa Corporation |
Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
|
GB0020953D0
(en)
|
2000-08-24 |
2000-10-11 |
Smithkline Beecham Biolog |
Vaccine
|
CA2420140A1
(fr)
|
2000-08-24 |
2002-02-28 |
Genentech, Inc. |
Compositions et procedes de diagnostic et traitement de tumeurs
|
US8314060B2
(en)
|
2000-09-05 |
2012-11-20 |
Biosight Ltd. |
Peptide conjugated anti-cancer prodrugs
|
AU2001290548A1
(en)
|
2000-09-11 |
2002-03-26 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
JP4908723B2
(ja)
|
2000-09-15 |
2012-04-04 |
ザイモジェネティクス, インコーポレイテッド |
炎症を治療するための方法
|
US6613567B1
(en)
|
2000-09-15 |
2003-09-02 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of Her-2 expression
|
US7491797B2
(en)
|
2000-09-15 |
2009-02-17 |
Genentech, Inc. |
PRO6308 polypeptide
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
EP1320604A2
(fr)
|
2000-09-18 |
2003-06-25 |
Biogen, Inc. |
Mutant cripto et utilisations de ce dernier
|
WO2002030268A2
(fr)
|
2000-10-13 |
2002-04-18 |
Eos Biotechnology, Inc. |
Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
ES2329012T3
(es)
|
2000-11-07 |
2009-11-20 |
Zymogenetics, Inc. |
Receptor del factor de necrosis tumoral humano.
|
US20020150573A1
(en)
|
2000-11-10 |
2002-10-17 |
The Rockefeller University |
Anti-Igalpha-Igbeta antibody for lymphoma therapy
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス,インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
WO2002061087A2
(fr)
|
2000-12-19 |
2002-08-08 |
Lifespan Biosciences, Inc. |
Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
|
AU2002243495A1
(en)
|
2001-01-12 |
2002-07-24 |
University Of Medicine And Dentistry Of New Jersey |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
US20030119126A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030119119A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
WO2002059377A2
(fr)
|
2001-01-24 |
2002-08-01 |
Protein Design Labs |
Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
|
WO2002060317A2
(fr)
|
2001-01-30 |
2002-08-08 |
Corixa Corporation |
Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
|
WO2002064798A1
(fr)
|
2001-02-12 |
2002-08-22 |
Bionomics Limited |
Sequences d'adn exprimees de façon differentielle dans des lignees cellulaires tumorales
|
WO2002071928A2
(fr)
|
2001-03-14 |
2002-09-19 |
Millennium Pharmaceuticals, Inc. |
Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires
|
EP1243276A1
(fr)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Prodrogues activables à séparateurs allongés et multiples
|
AU2002311787A1
(en)
|
2001-03-28 |
2002-10-15 |
Zycos Inc. |
Translational profiling
|
WO2003008537A2
(fr)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Sequences d'epitope
|
US6820011B2
(en)
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
MXPA03009510A
(es)
|
2001-04-17 |
2005-04-29 |
Univ Arkansas |
Secuencias de repeticion del gen ca125 y su uso para intervenciones de diagnosticos y terapeuticas.
|
AU2002309583A1
(en)
|
2001-04-18 |
2002-11-05 |
Protein Desing Labs, Inc. |
Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
CA2446788A1
(fr)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
|
US20030078399A1
(en)
|
2001-05-11 |
2003-04-24 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
|
CA2448123C
(fr)
|
2001-05-24 |
2012-09-11 |
Zymogenetics, Inc. |
Proteines hybrides taci-immunoglobuline
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US7157558B2
(en)
|
2001-06-01 |
2007-01-02 |
Genentech, Inc. |
Polypeptide encoded by a polynucleotide overexpresses in tumors
|
WO2002098358A2
(fr)
|
2001-06-04 |
2002-12-12 |
Eos Biotechnology, Inc. |
Procedes de diagnostic et de traitement du cancer prostatique androgene-dependant, cancer prostatique subissant un retrait d'androgenes et cancer prostatique androgene-independant
|
JP2005518185A
(ja)
|
2001-06-04 |
2005-06-23 |
キュラジェン コーポレイション |
新規タンパク質およびそれをコード化する核酸
|
DE60237917D1
(de)
|
2001-06-05 |
2010-11-18 |
Exelixis Inc |
Gfats als modifikatoren des p53-wegs und verwendungsverfahren
|
JP2004528043A
(ja)
|
2001-06-05 |
2004-09-16 |
エクセリクシス・インコーポレイテッド |
p53経路のモディファイヤーとしてのCHDsおよび使用方法
|
US7235358B2
(en)
|
2001-06-08 |
2007-06-26 |
Expression Diagnostics, Inc. |
Methods and compositions for diagnosing and monitoring transplant rejection
|
US7125663B2
(en)
|
2001-06-13 |
2006-10-24 |
Millenium Pharmaceuticals, Inc. |
Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
|
US7189507B2
(en)
|
2001-06-18 |
2007-03-13 |
Pdl Biopharma, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
CA2451465A1
(fr)
|
2001-06-18 |
2002-12-27 |
Eos Biotechnology Inc. |
Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
|
AU2002322280A1
(en)
|
2001-06-21 |
2003-01-21 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
|
WO2003002717A2
(fr)
|
2001-06-28 |
2003-01-09 |
Schering Corporation |
Activite biologique de ak155
|
WO2003004529A2
(fr)
|
2001-07-02 |
2003-01-16 |
Licentia Ltd. |
Materiaux de recepteur ephrine-tie et leurs procedes
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
WO2003003984A2
(fr)
|
2001-07-05 |
2003-01-16 |
Curagen Corporation |
Nouvelles proteines et nouveaux acides nucleiques codant ces proteines
|
US7446185B2
(en)
|
2001-07-18 |
2008-11-04 |
The Regents Of The University Of California |
Her2/neu target antigen and use of same to stimulate an immune response
|
WO2003009814A2
(fr)
|
2001-07-25 |
2003-02-06 |
Millennium Pharmaceuticals, Inc. |
Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
|
HUP0500992A3
(en)
|
2001-08-03 |
2007-11-28 |
Genentech Inc |
Tacis and br3 polypeptides and uses thereof
|
WO2003016475A2
(fr)
|
2001-08-14 |
2003-02-27 |
The General Hospital Corporation |
Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur
|
US20030092013A1
(en)
|
2001-08-16 |
2003-05-15 |
Vitivity, Inc. |
Diagnosis and treatment of vascular disease
|
AU2002313559A1
(en)
|
2001-08-23 |
2003-03-10 |
Oxford Biomedica (Uk) Limited |
Genes
|
US6902930B2
(en)
|
2001-08-29 |
2005-06-07 |
Vanderbilt University |
Human Mob-5 (IL-24) receptors and uses thereof
|
US20030124579A1
(en)
|
2001-09-05 |
2003-07-03 |
Eos Biotechnology, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
CA2459318C
(fr)
|
2001-09-06 |
2017-09-26 |
Agensys, Inc. |
Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
|
JP2005518782A
(ja)
|
2001-09-17 |
2005-06-30 |
プロテイン デザイン ラブス, インコーポレイテッド |
ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
|
ATE486092T1
(de)
|
2001-09-18 |
2010-11-15 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
US20050004017A1
(en)
|
2001-09-18 |
2005-01-06 |
Yuval Reiss |
Methods and compositions for treating hcap associated diseases
|
CA2460621A1
(fr)
|
2001-09-19 |
2003-03-27 |
Nuvelo, Inc. |
Nouveaux acides nucleiques et polypeptides
|
AU2002327792A1
(en)
|
2001-09-28 |
2003-04-07 |
Bing Yang |
Diagnosis and treatment of diseases caused by mutations in cd72
|
WO2003029421A2
(fr)
|
2001-10-03 |
2003-04-10 |
Origene Technologies, Inc. |
Genes regules du cancer du sein
|
US20050130117A1
(en)
|
2001-10-03 |
2005-06-16 |
Davis Cong L. |
Modulators of lymphocyte activation and migration
|
CA2842429A1
(fr)
|
2001-10-19 |
2003-05-01 |
Genentech, Inc. |
Compositions et procedes pour le diagnostic et le traitement d'affections intestinales inflammatoires
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7825089B2
(en)
|
2001-10-24 |
2010-11-02 |
National Jewish Health |
Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
|
BR0213738A
(pt)
|
2001-10-31 |
2006-11-21 |
Alcon Inc |
proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma
|
WO2003042661A2
(fr)
|
2001-11-13 |
2003-05-22 |
Protein Design Labs, Inc. |
Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
|
US20030232350A1
(en)
|
2001-11-13 |
2003-12-18 |
Eos Biotechnology, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
US7344843B2
(en)
|
2001-11-29 |
2008-03-18 |
Serono Genetics Institute S.A. |
Agonists and antagonists of prolixin for the treatment of metabolic disorders
|
AU2002349784A1
(en)
|
2001-12-03 |
2003-06-17 |
Asahi Kasei Pharma Corporation |
Nf-kappab activating genes
|
WO2003054152A2
(fr)
|
2001-12-10 |
2003-07-03 |
Nuvelo, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
US20030134790A1
(en)
|
2002-01-11 |
2003-07-17 |
University Of Medicine And Dentistry Of New Jersey |
Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
|
US7452675B2
(en)
|
2002-01-25 |
2008-11-18 |
The Queen's Medical Center |
Methods of screening for TRPM4b modulators
|
EP1476120B1
(fr)
|
2002-02-21 |
2010-09-29 |
Duke University |
Methodes therapeutiques utilisant des anticorps anti-cd22
|
CA2476518A1
(fr)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions et methodes de traitement de maladies relatives au systeme immunitaire
|
US20030232013A1
(en)
|
2002-02-22 |
2003-12-18 |
Gary Sieckman |
Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
|
US20030219795A1
(en)
|
2002-03-01 |
2003-11-27 |
Marcia Belvin |
SCDs as modifiers of the p53 pathway and methods of use
|
US20050287147A1
(en)
|
2002-05-15 |
2005-12-29 |
Reinhard Ebner |
Cancer-linked gene as target for chemotherapy
|
EP2258712A3
(fr)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
|
CA2486490A1
(fr)
|
2002-03-19 |
2003-12-31 |
Curagen Corporation |
Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation
|
JP2005534286A
(ja)
|
2002-03-21 |
2005-11-17 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
キナーゼインヒビターの同定
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
JP2005520566A
(ja)
|
2002-03-22 |
2005-07-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Cripto特異的抗体
|
JP2005521429A
(ja)
|
2002-03-25 |
2005-07-21 |
ユーエービー リサーチ ファウンデーション |
Fcレセプターホモログ、試薬およびこれらの使用
|
AU2003222103A1
(en)
|
2002-03-28 |
2003-10-13 |
Idec Pharmaceuticals Corporation |
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
|
US20030194704A1
(en)
|
2002-04-03 |
2003-10-16 |
Penn Sharron Gaynor |
Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
|
BR0308953A
(pt)
|
2002-04-05 |
2006-03-14 |
Agensys Inc |
composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
|
WO2003087768A2
(fr)
|
2002-04-12 |
2003-10-23 |
Mitokor |
Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
|
CA2481507A1
(fr)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
|
US20030224467A1
(en)
|
2002-04-17 |
2003-12-04 |
Osborne C. Kent |
AIB1 as a prognostic marker and predictor of resistance to endocrine therapy
|
WO2003093444A2
(fr)
|
2002-05-03 |
2003-11-13 |
Incyte Corporation |
Transporteurs et canaux ioniques
|
WO2005117986A2
(fr)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Conjugues de medicaments anticorps et procedes correspondants
|
KR101059041B1
(ko)
|
2002-05-17 |
2011-08-24 |
셀진 코포레이션 |
암과 다른 질병의 치료 및 처리를 위한 선택적 사이토카인억제 약물을 사용하는 방법 및 조성물
|
US20030224454A1
(en)
|
2002-05-30 |
2003-12-04 |
Ryseck Rolf Peter |
Human solute carrier family 7, member 11 (hSLC7A11)
|
CA2488441C
(fr)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Bibliotheques de phages et anticorps synthetiques
|
EP1575492A4
(fr)
|
2002-06-04 |
2007-05-09 |
Avalon Pharmaceuticals |
Gene lie au cancer comme cible de chimiotherapie
|
AU2003240495A1
(en)
|
2002-06-04 |
2003-12-19 |
Incyte Corporation |
Diagnostics markers for lung cancer
|
WO2003104270A2
(fr)
|
2002-06-06 |
2003-12-18 |
Ingenium Pharmaceuticals Ag |
Genes de la duduline 2, produits d'expression, modele animal non humain : utilisations dans les maladies hematologiques humaines
|
EP2275544A3
(fr)
|
2002-06-06 |
2011-03-30 |
Oncotherapy Science, Inc. |
Gènes et polypeptides en rapport avec les cancers du colon chez l'homme
|
AU2003249691A1
(en)
|
2002-06-07 |
2003-12-22 |
Avalon Pharmaceuticals, Inc |
Cancer-linked gene as target for chemotherapy
|
AU2003245441A1
(en)
|
2002-06-12 |
2003-12-31 |
Avalon Pharmaceuticals, Inc. |
Cancer-linked gene as target for chemotherapy
|
US20040249130A1
(en)
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
AU2003247576A1
(en)
|
2002-06-18 |
2003-12-31 |
Archemix Corp. |
Aptamer-toxin molecules and methods for using same
|
CA2489803A1
(fr)
|
2002-06-20 |
2003-12-31 |
The Regents Of The University Of California |
Compositions et procedes de modulation de l'activite lymphocytaire
|
US20060275287A1
(en)
|
2002-06-21 |
2006-12-07 |
Brad St Croix |
Scroll compressor
|
AU2003281515A1
(en)
|
2002-07-19 |
2004-02-09 |
Cellzome Ag |
Protein complexes of cellular networks underlying the development of cancer and other diseases
|
NZ537781A
(en)
|
2002-07-25 |
2008-04-30 |
Genentech Inc |
Taci antibodies and uses thereof
|
JP4741838B2
(ja)
|
2002-07-31 |
2011-08-10 |
シアトル ジェネティクス,インコーポレーテッド |
癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
|
WO2004015426A1
(fr)
|
2002-08-06 |
2004-02-19 |
Bayer Healthcare Ag |
Agents diagnostiques et therapeutiques contre des maladies associees au recepteur 5 de la chemokine cxc humain (cxcr5)
|
JP2004121218A
(ja)
|
2002-08-06 |
2004-04-22 |
Jenokkusu Soyaku Kenkyusho:Kk |
気管支喘息または慢性閉塞性肺疾患の検査方法
|
ATE499116T1
(de)
|
2002-08-16 |
2011-03-15 |
Immunogen Inc |
Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
|
EP1578371A4
(fr)
|
2002-08-19 |
2009-05-20 |
Genentech Inc |
Compositions et methodes de diagnostic et de traitement des tumeurs
|
WO2004020583A2
(fr)
|
2002-08-27 |
2004-03-11 |
Bristol-Myers Squibb Company |
Identification de polynucleotides pour predire l'activite de composes interagissant avec et/ou modulant des proteines tyrosine kinases et/ou des voies de proteines tyrosine kinases dans des cellules mammaires
|
WO2004020595A2
(fr)
|
2002-08-29 |
2004-03-11 |
Five Prime Therapeutics, Inc. |
Nouveaux polypeptides humains codes par des polynucleotides
|
AU2002951346A0
(en)
|
2002-09-05 |
2002-09-26 |
Garvan Institute Of Medical Research |
Diagnosis of ovarian cancer
|
CA2496888A1
(fr)
|
2002-09-06 |
2004-03-18 |
Mannkind Corporation |
Sequences de sites antigeniques
|
JP2006513702A
(ja)
|
2002-09-09 |
2006-04-27 |
ヌラ インコーポレーティッド |
Gタンパク質共役受容体およびその使用
|
JP2004113151A
(ja)
|
2002-09-27 |
2004-04-15 |
Sankyo Co Ltd |
癌遺伝子及びその用途
|
CA2501131A1
(fr)
|
2002-10-04 |
2004-04-22 |
Van Andel Research Institute |
Sous classification moleculaire de tumeurs renales et decouverte de nouveaux marqueurs diagnostiques
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
CA2499300A1
(fr)
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methodes et compositions pouvant augmenter la production d'anticorps
|
CA2503748A1
(fr)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions et procedes de traitement des maladies liees aux cellules k naturelles
|
CA2503621A1
(fr)
|
2002-11-13 |
2004-05-27 |
Genentech, Inc. |
Procedes et compositions pour diagnostiquer une dysplasie
|
EP1578372A4
(fr)
|
2002-11-15 |
2007-10-17 |
Univ Arkansas |
Gene ca125 et utilisation de celui-ci aux fins d'interventions diagnostiques et therapeutiques
|
ES2392511T3
(es)
|
2002-11-15 |
2012-12-11 |
Musc Foundation For Research Development |
Moduladores de complemento dianas sobre el receptor 2 de complemento
|
US20080213166A1
(en)
|
2002-11-20 |
2008-09-04 |
Biogen Idec Inc. |
Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas
|
CA2507044A1
(fr)
|
2002-11-21 |
2004-06-10 |
Mary Lucero |
Modulation purinergique d'odeur
|
WO2004048938A2
(fr)
|
2002-11-26 |
2004-06-10 |
Protein Design Labs, Inc. |
Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
|
US20070154886A1
(en)
|
2002-12-06 |
2007-07-05 |
Macina Roberto A |
Composition, splice variants and methods relating to ovarian specific genes and proteins
|
US20040157278A1
(en)
|
2002-12-13 |
2004-08-12 |
Bayer Corporation |
Detection methods using TIMP 1
|
PT1572744E
(pt)
|
2002-12-16 |
2010-09-07 |
Genentech Inc |
Variantes de imunoglobulina e utilizações destas
|
ES2388280T3
(es)
|
2002-12-20 |
2012-10-11 |
Abbott Biotherapeutics Corp. |
Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos
|
US20050249671A9
(en)
|
2002-12-23 |
2005-11-10 |
David Parmelee |
Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
|
WO2004063709A2
(fr)
|
2003-01-08 |
2004-07-29 |
Bristol-Myers Squibb Company |
Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique
|
US20050181375A1
(en)
|
2003-01-10 |
2005-08-18 |
Natasha Aziz |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
|
US20050227301A1
(en)
|
2003-01-10 |
2005-10-13 |
Polgen |
Cell cycle progression proteins
|
US20040171823A1
(en)
|
2003-01-14 |
2004-09-02 |
Nadler Steven G. |
Polynucleotides and polypeptides associated with the NF-kappaB pathway
|
JP2007520996A
(ja)
|
2003-01-15 |
2007-08-02 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
44390、54181、211、5687、884、1405、636、4421、5410、30905、2045、16405、18560、2047、33751、52872、14063、20739、32544、43239、44373、51164、53010、16852、1587、2207、22245、2387、52908、69112、14990、18547、115、579、15985、15625、760、18603、2395、2554、8675、32720、4809、14303、16816、17827、32620、577、619、1423、2158、8263、15402、16209、16386、21165、30911、41897、1643、2543、9626、13231、32409、84260、2882、8203、32678または55053を用いて泌尿器科障害を処置するための方法および組成物
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7575893B2
(en)
|
2003-01-23 |
2009-08-18 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
US20060228710A1
(en)
|
2003-02-14 |
2006-10-12 |
Morris David W |
Novel therapeutic targets in cancer
|
US20030224411A1
(en)
|
2003-03-13 |
2003-12-04 |
Stanton Lawrence W. |
Genes that are up- or down-regulated during differentiation of human embryonic stem cells
|
DE60326060D1
(de)
|
2003-03-31 |
2009-03-19 |
Council Scient Ind Res |
Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
AU2004284075A1
(en)
|
2003-10-22 |
2005-05-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
PT2489364E
(pt)
|
2003-11-06 |
2015-04-16 |
Seattle Genetics Inc |
Compostos de monometilvalina conjugados com anticorpos
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
JP5166861B2
(ja)
|
2004-03-09 |
2013-03-21 |
スピロゲン リミティッド |
ピロロベンゾジアゼピン
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
ES2403055T3
(es)
|
2004-04-13 |
2013-05-13 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-P-selectina
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
DK2135881T3
(da)
|
2005-06-20 |
2011-12-05 |
Genentech Inc |
Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
|
US20070060534A1
(en)
|
2005-06-30 |
2007-03-15 |
Threshold Pharmaceuticals, Inc. |
Anthracycline analogs
|
WO2007008848A2
(fr)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Composes de monomethylvaline presentant des modifications carboxy phenylalanine a la terminaison c
|
WO2007008603A1
(fr)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
|
EP1957531B1
(fr)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
|
WO2007064919A2
(fr)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Polypeptides de liaison avec des sequences de diversite limitees
|
EP1813614B1
(fr)
|
2006-01-25 |
2011-10-05 |
Sanofi |
Agents cytotoxiques comprenant de nouveaux dérivés de Tomaymycine
|
EP2016101A2
(fr)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Polypeptides de liaison à squelettes optimisés
|
WO2007147901A1
(fr)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production d'anticorps bispécifiques
|
ZA200900545B
(en)
|
2006-07-18 |
2010-03-31 |
Sanofi Aventis |
Antagonist antibody against EPHA2 for the treatment of cancer
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
DK2019104T3
(da)
|
2007-07-19 |
2013-12-16 |
Sanofi Sa |
Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
|
CA2709847C
(fr)
|
2008-01-07 |
2018-07-10 |
Amgen Inc. |
Methode de fabrication de molecules heterodimeres fc d'anticorps utilisant les effets de conduite electrostatique
|
US8742076B2
(en)
|
2008-02-01 |
2014-06-03 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
AR072804A1
(es)
|
2008-07-15 |
2010-09-22 |
Genentech Inc |
Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
|
NZ594177A
(en)
|
2009-02-05 |
2014-02-28 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
EP3485912A1
(fr)
|
2009-04-08 |
2019-05-22 |
Faulstich, Heinz, Dr. |
Constituants thérapeutiques contenant de l'amatoxine de liaison à la surface cellulaire destinés à la thérapie des tumeurs
|
SI2528625T1
(sl)
|
2010-04-15 |
2013-11-29 |
Spirogen Sarl |
Pirolobenzodiazepini in njihovi konjugati
|
CA2796633C
(fr)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production de proteines heteromultimeres
|
NZ603732A
(en)
|
2010-06-14 |
2015-02-27 |
Hoffmann La Roche |
Cell-penetrating peptides and uses therof
|
ES2402254T3
(es)
|
2010-09-30 |
2013-04-30 |
Heidelberg Pharma Ag |
Conjugados de amatoxinas con ligadores mejorados
|
WO2012074757A1
(fr)
|
2010-11-17 |
2012-06-07 |
Genentech, Inc. |
Conjugués d'anticorps alaninyl-maytansinol
|
US8470984B2
(en)
|
2010-12-02 |
2013-06-25 |
Nerviano Medical Sciences S.R.L. |
Process for the preparation of morpholinyl anthracycline derivatives
|
EP2497499A1
(fr)
|
2011-03-10 |
2012-09-12 |
Heidelberg Pharma GmbH |
Conjugués d'amatoxine avec liens améliorés
|
RS57895B1
(sr)
|
2011-03-29 |
2019-01-31 |
Roche Glycart Ag |
Fc varijante antitela
|
KR101877598B1
(ko)
*
|
2011-10-14 |
2018-07-11 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
MX2015000357A
(es)
*
|
2012-07-09 |
2015-05-12 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd22.
|
WO2014043403A1
(fr)
|
2012-09-12 |
2014-03-20 |
Agensys, Inc. |
Dérivés d'amatoxine et conjugués à base de ceux-ci, à perméabilité cellulaire, en tant qu'inhibiteurs de l'arn polymérase
|
PL2917195T3
(pl)
*
|
2012-11-05 |
2018-04-30 |
Pfizer Inc. |
Analogi spliceostatyny
|
EP2774624A1
(fr)
|
2013-03-04 |
2014-09-10 |
Heidelberg Pharma GmbH |
Dérivés d'amatoxine
|
SG11201507214SA
(en)
*
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
US20140349944A1
(en)
|
2013-05-23 |
2014-11-27 |
Musc Foundation For Research Development |
Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
|
SG11201601005XA
(en)
*
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
WO2015095227A2
(fr)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
|
WO2015095212A1
(fr)
*
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
|
JP6236540B2
(ja)
*
|
2014-01-27 |
2017-11-22 |
ファイザー・インク |
二官能性細胞毒性剤
|
JP6622293B2
(ja)
|
2014-09-12 |
2019-12-18 |
ジェネンテック, インコーポレイテッド |
アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
|
WO2016044560A1
(fr)
*
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
|
MA43345A
(fr)
*
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|